Holen Sie sich die Stockscreener-App
3.11
7.99%
0.23
Handel nachbörslich:
3.08
-0.03
-0.96%
Schlusskurs vom Vortag:
$2.88
Offen:
$2.88
24-Stunden-Volumen:
876.44K
Relative Volume:
0.73
Marktkapitalisierung:
$186.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.95M
KGV:
-3.7024
EPS:
-0.84
Netto-Cashflow:
$-33.46M
1W Leistung:
-4.31%
1M Leistung:
+41.04%
6M Leistung:
-22.44%
1J Leistung:
-59.66%
1-Tages-Spanne:
$2.8214
$3.185
1-Wochen-Bereich:
$2.81
$3.2596
52-Wochen-Spanne:
$1.61
$11.20
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Firmenname
Larimar Therapeutics Inc
Sektor
Branche
Telefon
844-511-9056
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Vergleichen Sie LRMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.11 | 186.32M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-29 | Eingeleitet | Truist | Buy |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-03 | Eingeleitet | Wedbush | Outperform |
| 2024-10-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-03 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-19 | Eingeleitet | Guggenheim | Buy |
| 2022-02-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-02-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks
Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Larimar: Q1 Earnings Snapshot - MySA
Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView
Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX
Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus
Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com
Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus
Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan
Larimar Therapeutics awards key executives performance-based stock - MSN
Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX
Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com
Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News
The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com
Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com
Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha
An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com
Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News
Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World
HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World
LRMR stock touches 52-week low at $2.21 amid market challenges - Investing.com
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World
Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK
Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks
FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia
Larimar: Q4 Earnings Snapshot - mySA
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener
FDA open to new surrogate endpoint for FA drug approval - Investing.com India
Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener
Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):